Financial health
- The company is unprofitable; at its current free-cash-flow burn it has roughly 2.5 years of cash runway.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$36M | — | — | -$26M | — | $66M |
| 2024 | — | -$27M | — | — | -$15M | — | $94M |
| 2023 | — | -$24M | — | — | -$21M | — | $14M |
| 2022 | — | -$15M | — | — | -$14M | — | $35M |
| 2021 | — | -$10M | — | — | -$9M | — | $50M |
| 2020 | — | $7M | — | — | — | — | $290670 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$9M | — | — | -$11M | — | $55M |
| Dec '25 | — | -$13M | — | — | -$9M | — | $66M |
| Sep '25 | — | -$10M | — | — | -$7M | — | $77M |
| Jun '25 | — | -$9M | — | — | -$6M | — | $84M |
| Mar '25 | — | -$5M | — | — | -$5M | — | $89M |
| Dec '24 | — | -$3M | — | — | -$5M | — | $94M |
| Sep '24 | — | -$17M | — | — | -$2M | — | $85M |
| Jun '24 | — | -$2M | — | — | -$3M | — | $102M |
| Mar '24 | — | -$4M | — | — | -$4M | — | $10M |
| Dec '23 | — | -$7M | — | — | -$7M | — | $14M |
| Sep '23 | — | -$6M | — | — | -$3M | — | $22M |
| Jun '23 | — | -$5M | — | — | -$5M | — | $25M |
| Mar '23 | — | -$6M | — | — | -$6M | — | $30M |
| Dec '22 | — | -$4M | — | — | -$4M | — | $35M |
| Sep '22 | — | -$4M | — | — | -$3M | — | $39M |
| Jun '22 | — | -$4M | — | — | -$3M | — | $43M |
| Mar '22 | — | -$3M | — | — | -$4M | — | $46M |
| Dec '21 | — | -$3M | — | — | -$5M | — | $50M |
| Sep '21 | — | -$1M | — | — | -$43633 | — | $419152 |
| Jun '21 | — | -$5M | — | — | -$2M | — | — |
See the revenue and net-income charts above for Context Therapeutics Inc.'s multi-year trend.
As of FY2025, Context Therapeutics Inc. reported — of total debt against $66M of cash.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.